Physician profile
Amitkumar Patel
NPI 1154564698
$2,848.77
in general payments reported to CMS, 2019-2025
26 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.69 · 2022: $95.18 · 2023: $1,622 · 2024: $552 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $353.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $268.85 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $254.58 | 2022-2023 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $185.28 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $180.02 | 2023-2025 | Veozah |
| Medtronic, INC. | $148.25 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Glaxosmithkline, LLC. | $127.89 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $123.63 | 2019-2025 | |
| Averitas Pharma INC. | $118.76 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.89 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.95 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $73.57 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $62.75 | 2023-2024 | Dexcom G6 Transmitter |
| Halozyme INC | $58.89 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.93 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $39.20 | 2023-2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $37.35 | 2023 | |
| Antares Pharma, INC. | $31.81 | 2024-2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $30.50 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $28.74 | 2023 | Auvelity |
| Amarin Pharma, INC. | $24.76 | 2023 | |
| Ironshore Pharmaceuticals INC. | $24.31 | 2023 | Jornay Pm |
| Cranial Technologies, INC | $20.15 | 2023 | Doc Band |
| Currax Pharmaceuticals LLC | $17.44 | 2023 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.